Alnylam Pharmaceuticals Inc., a Cambridge RNAi-focused therapeutics firm, is extending a research collaboration originally started in 2009 with AlCana Technologies Inc. and The University of British Columbia (UBC). The collaboration focuses on RNAi therapeutics delivery stemming from the discovery of cationic lipids used in lipid nanoparticles.
Alnylam is paying for the research collaboration, though no financial details were disclosed by the companies. Per terms of the agreement though, the Cambridge biotech will hold exclusive rights to any new RNAi developments stemming from the collaboration, in addition to rights to sublicense the intellectual property to Alnylam partners. Among those partners is Canadian firm Tekmira Pharmaceuticals Corp. (TZX: TKM), which has the right to use research developed through the AlCana and UBC collaboration under Alnylam’s IP for Tekmira’s own research in its InterfeRx program.